2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

Singh S, Youssef EG, Barbarino A, Hautau H, Nabeela S, Gebremariam T, Alkhazraji S, Ostroff G, Christensen D, Cochrane T, Ibrahim AS. Next-generation Candida albicans[...]

Sodium-Glucose Cotransporter-2 Inhibitors and Ketoacid Diets for Diabetic Kidney Disease

Kopple JD. Sodium-Glucose Cotransporter-2 Inhibitors and Ketoacid Diets for Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2025 Dec 12. doi: 10.2215/CJN.0000000958. Epub ahead of[...]

Imaging Inflammation: Epicardial Fat Density as an Imaging Marker of Cardiovascular Risk

Abbas N, Budoff M, Lakshmanan S. Imaging Inflammation: Epicardial Fat Density as an Imaging Marker of Cardiovascular Risk. Heart Int. 2025 Nov 24;19(2):29-34. doi: 10.17925/HI.2025.19.2.4.[...]